Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von sexuellen Funktionsstörungen im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Althof SE, McMahon CG, Waldinger MD et al (2014) An update of the International Society of Sexual Medicine’s Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). Sex Med 2: 60–90
Baldwin DS, Chrones L, Florea I et al (2016) The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies J Psychopharmacol 30(3): 242–252
de Boer MK, Castelein S, Wiersma D et al (2015) The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 41: 674–686
Gacci M, Andersson KE, Chapple C et al (2016) Latest evidence of the use of phosphodiesterase 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70(1): 124–133
Gao L, Yang L, Qian S et al (2015) Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet 133(2): 139–145
Hartmann U (2016a) Hypersexuelle Störung – Teil 1: Kategorisierung bleibt schwierig. DNP – Der Neurologe & Psychiater 17: 28–33
Hartmann U (2016b) Hypersexuelle Störung – Teil 2: Diagnostik und Therapie der »Sexsucht«. DNP – Der Neurologe & Psychiater 17: 34–41
Joffe HV, Chang C, Sewell C et al (2016) FDA approval of flibanserin – treating hypoactive sexual desire disorder. N Engl J Med 374: 101–104
Kingsberg SA, Clayton AH, Pfaus JG (2015) The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of Hypoactive Sexual Desire Disorder. CNS Drugs 29: 915–933
La Torre A, Conca A, Duffy D et al (2013) Sexual dysfunction related to psychotropic drugs: a critical review. Part II: antipsychotics. Pharmacopsychiatry 46(6): 201–208
La Torre A, Giupponi G, Duffy DM et al (2014) Sexual dysfunction related to psychotropic drugs: a critical review. Part III: mood stabilizers and anxiolytic drugs. Pharmacopsychiatry 47(1): 1–6
La Torre A, Giupponi G, Duffy DM et al (2015) Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry 48: 1–6
Loeb S, Folkvaljon Y, Lambe M et al (2015) Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 313: 2449–2455
Malik P, Kemmler G, Hummer M et al; and the EUFEST Study Group (2011) Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 31: 274–280
Men C, Yu L, Yuan H et al (2016) Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis. Andrologia [Epub ahead of print]
Müller MJ (2011) Sexuelle Funktionsstörungen – Wenn Psychopharmaka das Liebesleben lähmen. NeuroTransmitter 2: 52–59
Schmidt HM, Hagen M, Kriston L et al (2012) Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 11: CD003546
Ventimiglia E, Capogrosso P, Montorsi F et al (2016) The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf 15: 141–152
Vigen R, O’Donnell CI, Barón AE et al (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310(17): 1829–1836
Wenzel-Seifert K, Ostermaier CP, Conca A et al (2015) Sexuelle Funktionsstörungen unter antidepressiver Pharmakotherapie. Psychopharmakotherapie 22: 205–211
Yee A, Loh HS, Hisham Hashim HM et al (2014) The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: a meta-analysis study. J Sex Med 11(1): 22–32
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Müller, M., Benkert, O. (2017). Medikamente zur Behandlung von sexuellen Funktionsstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-50333-1_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-50332-4
Online ISBN: 978-3-662-50333-1
eBook Packages: Medicine (German Language)